Continuous Follow-Up: Our medical team monitors your response energy level, mental clarity, fatigue, and other changes after each session
DSIP Cycle Length
The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study
However, published human pharmacokinetic data comparing oral to injectable absorption at equivalent doses has not been established in peer-reviewed literature
Common Side Effects (Generally Mild): Temporary injection site reactions (redness, slight swelling) Mild fatigue initially (as metabolism adjusts) Occasional flushing or warmth Slight changes in appetite Contraindications and Precautions: Pregnancy or breastfeeding (insufficient safety data) Active cancer (theoretical concerns about growth pathways) Severe kidney or liver disease (requires monitoring) Hypoglycemia risk (monitor if on diabetes medications) Medical Monitoring: At The Lamkin Clinic, we monitor MOTS-C patients with: Baseline metabolic labs (glucose, HbA1c, insulin, lipids) Follow-up testing at 8-12 weeks Body composition analysis Assessment of symptoms and energy levels Adjustment of other medications as metabolism improves Important: MOTS-C should only be used under the guidance of a qualified healthcare provider experienced in peptide therapy
